Astria Therapeutics (ATXS)
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunologi...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 12.580
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 13.290
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Astria Therapeutics Analyst Rating
View moreForecast & Rating
Nov 12, 2025Price forecast
$24.6095.55%
Forecast & RatingHold
8analysts
- Strong buy12.50%
- Buy0.00%
- Hold87.50%
- Sell0.00%
- Strong sell0.00%
News
- prnewswire · Apr 26 at 07:12 PM
20:10 ETAscletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
- MorningStar · Apr 9 at 12:30 AM
Egetis Appoints Tiago Nunes as Chief Medical Officer
- Tip Ranks · Mar 24 at 09:35 AM
Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report
- StockTitan · Feb 24 at 03:30 AM
Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board | COSM Stock News
- Unusual Whales · Feb 19 at 08:28 AM
Axtria releases U.S. Incentive Compensation Benchmarking Study 2026 to aid life sciences, enhancing performance.
- rttnews · Feb 4 at 07:27 AM
Will BioCryst's ORLADEYO Hit The $1 Billion Sales Mark?
